Canaccord analyst Tania Armstrong-Whitworth downgraded Knight Therapeutics (KHTRF) to Hold from Buy with a C$6.50 price target
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KHTRF:
- Knight Therapeutics Achieves Record Revenues and Expands Product Approvals
- Knight Therapeutics reports FY24 EPS C$0.04 vs. (C$0.16) last year
- Knight Therapeutics sees FY25 revenue C$390M-C$405M
- Knight Therapeutics (KHTRF) Q4 Earnings Cheat Sheet
- Knight Therapeutics price target raised to C$8 from C$7.50 at Raymond James